WO2007073932A3 - Proteinbasiertes trägersystem zur resistenzüberwindung von tumorzellen - Google Patents

Proteinbasiertes trägersystem zur resistenzüberwindung von tumorzellen Download PDF

Info

Publication number
WO2007073932A3
WO2007073932A3 PCT/EP2006/012524 EP2006012524W WO2007073932A3 WO 2007073932 A3 WO2007073932 A3 WO 2007073932A3 EP 2006012524 W EP2006012524 W EP 2006012524W WO 2007073932 A3 WO2007073932 A3 WO 2007073932A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein
delivery system
tumour cells
based delivery
overcoming resistance
Prior art date
Application number
PCT/EP2006/012524
Other languages
English (en)
French (fr)
Other versions
WO2007073932A2 (de
Inventor
Sebastian Dreis
Klaus Langer
Joerg Kreuter
Martin Michaelis
Jindrich Cinatl
Original Assignee
Lohmann Therapie Syst Lts
Sebastian Dreis
Klaus Langer
Joerg Kreuter
Martin Michaelis
Jindrich Cinatl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lohmann Therapie Syst Lts, Sebastian Dreis, Klaus Langer, Joerg Kreuter, Martin Michaelis, Jindrich Cinatl filed Critical Lohmann Therapie Syst Lts
Priority to NZ569898A priority Critical patent/NZ569898A/en
Priority to US12/087,175 priority patent/US20090181090A1/en
Priority to BRPI0620800A priority patent/BRPI0620800A2/pt
Priority to CA002631003A priority patent/CA2631003A1/en
Priority to EP06841159A priority patent/EP1965769A2/de
Priority to AU2006331030A priority patent/AU2006331030A1/en
Priority to JP2008547893A priority patent/JP2009521515A/ja
Publication of WO2007073932A2 publication Critical patent/WO2007073932A2/de
Publication of WO2007073932A3 publication Critical patent/WO2007073932A3/de
Priority to IL192343A priority patent/IL192343A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Die Erfindung betrifft Nanopartikel, deren Partikelmatrix auf mindestens einem Protein basieren und in die mindestens ein Wirkstoff eingebettet ist, Verfahren zur Herstellung der Nanopartikel mit mindestens einem in die Proteinmatrix eingebundenen Wirkstoff sowie die Verwendung derartiger Nanopartikel zur Behandlung von Tumoren, insbesondere zur Behandlung von Tumoren, die resistent gegen Chemotherapeutika sind.
PCT/EP2006/012524 2005-12-27 2006-12-22 Proteinbasiertes trägersystem zur resistenzüberwindung von tumorzellen WO2007073932A2 (de)

Priority Applications (8)

Application Number Priority Date Filing Date Title
NZ569898A NZ569898A (en) 2005-12-27 2006-12-22 Protein-based delivery system for overcoming resistance in tumour cells
US12/087,175 US20090181090A1 (en) 2005-12-27 2006-12-22 Protein-Based Carrier System for Overcoming Resistance in Tumour Cells
BRPI0620800A BRPI0620800A2 (pt) 2005-12-27 2006-12-22 uso de nano partículas compreendendo uma matriz de pelo menos uma proteína na qual pelo menos um agente ativo anti neoplástico é embutido
CA002631003A CA2631003A1 (en) 2005-12-27 2006-12-22 Protein-based delivery system for overcoming resistance in tumour cells
EP06841159A EP1965769A2 (de) 2005-12-27 2006-12-22 Proteinbasiertes trägersystem zur resistenzüberwindung von tumorzellen
AU2006331030A AU2006331030A1 (en) 2005-12-27 2006-12-22 Protein-based delivery system for overcoming resistance in tumour cells
JP2008547893A JP2009521515A (ja) 2005-12-27 2006-12-22 腫瘍細胞における耐性を克服するためのタンパク質ベースの担体システム
IL192343A IL192343A0 (en) 2005-12-27 2008-06-19 Protein-based delivery system for overcoming resistance in tumor cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005062440.5 2005-12-27
DE102005062440A DE102005062440B4 (de) 2005-12-27 2005-12-27 Proteinbasiertes Trägersystem zur Resistenzüberwindung von Tumorzellen

Publications (2)

Publication Number Publication Date
WO2007073932A2 WO2007073932A2 (de) 2007-07-05
WO2007073932A3 true WO2007073932A3 (de) 2007-09-27

Family

ID=38110688

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/012524 WO2007073932A2 (de) 2005-12-27 2006-12-22 Proteinbasiertes trägersystem zur resistenzüberwindung von tumorzellen

Country Status (14)

Country Link
US (1) US20090181090A1 (de)
EP (1) EP1965769A2 (de)
JP (1) JP2009521515A (de)
KR (1) KR20080081080A (de)
CN (1) CN101346131A (de)
AU (1) AU2006331030A1 (de)
BR (1) BRPI0620800A2 (de)
CA (1) CA2631003A1 (de)
DE (1) DE102005062440B4 (de)
IL (1) IL192343A0 (de)
NZ (1) NZ569898A (de)
RU (1) RU2404916C2 (de)
WO (1) WO2007073932A2 (de)
ZA (1) ZA200804572B (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0811175D0 (en) * 2008-06-18 2008-07-23 Prendergast Patrick T Anti-tumour compositions and methods
WO2011017835A1 (en) * 2009-08-11 2011-02-17 Nanjing University Preparation method of protein or peptide nanoparticles for in vivo drug delivery by unfolding and refolding
US20120263739A1 (en) * 2009-11-13 2012-10-18 Merck Patent Gmbh Anti integrin antibodies linked to nanoparticles loaded with chemotherapeutic agents
CN103202812B (zh) * 2010-08-09 2015-10-28 南京大学 一种制备用于体内递送药理活性物质的蛋白纳米粒的方法
JP6320042B2 (ja) 2011-02-11 2018-05-09 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 前立腺癌治療のための抗アルファ−ｖインテグリン抗体
RU2504018C1 (ru) * 2012-05-28 2014-01-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Рязанский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения и социального развития Российской Федерации Способ моделирования состояния индукции функциональной активности гликопротеина-р финастеридом в эксперименте
CN102846562B (zh) * 2012-09-28 2014-11-26 山东大学 一种半乳糖介导的冬凌草甲素白蛋白纳米粒及其制备方法
EP2917183A1 (de) * 2012-11-12 2015-09-16 Ignyta, Inc. Bendamustinderivate und verfahren zur verwendung davon
CN103275965A (zh) * 2013-05-22 2013-09-04 武汉理工大学 一种自恢复多功能软包埋细胞固载体系及其制备方法
CN103611169A (zh) * 2013-12-02 2014-03-05 东南大学 具有靶向性的免疫磁性白蛋白纳米球及制备方法
AU2015258891A1 (en) * 2014-05-16 2016-12-01 Dana-Farber Cancer Institute, Inc. Protein-based particles for drug delivery
WO2016020697A1 (en) * 2014-08-06 2016-02-11 Cipla Limited Pharmaceutical compositions of polymeric nanoparticles
US20160199497A1 (en) * 2014-09-10 2016-07-14 Purdue Research Foundation Cholesterol Ester-Depleting Nanomedicine for Non-toxic Cancer Chemotherapy
CN104211815B (zh) * 2014-09-12 2017-06-06 华东理工大学 一种铁蛋白重链亚基纳米载药系统及其制备方法与应用
CN104382854A (zh) * 2014-10-09 2015-03-04 唐春林 一种多柔比星脂质微泡及其制备方法
CN104324005A (zh) * 2014-10-09 2015-02-04 唐春林 一种争光霉素脂质微泡及其制备方法
CN104382904B (zh) * 2014-10-09 2018-02-13 唐春林 一种长春新碱脂质微泡及其制备方法
US10265413B2 (en) 2014-11-05 2019-04-23 University Of The Sciences In Philadelphia High molecular weight biodegradable gelatin-doxorubicin conjugate
MA41866A (fr) * 2015-03-31 2018-02-06 Massachusetts Gen Hospital Molécules à auto-assemblage pour l'administration ciblée de médicaments
CN105343005A (zh) * 2015-11-06 2016-02-24 中国药科大学 一种新型中药纳米粒口服吸收增强技术
WO2017120504A1 (en) 2016-01-08 2017-07-13 Durfee Paul N Osteotropic nanoparticles for prevention or treatment of bone metastases
WO2018160865A1 (en) * 2017-03-01 2018-09-07 Charles Jeffrey Brinker Active targeting of cells by monosized protocells
CN108741097A (zh) * 2018-05-17 2018-11-06 华南理工大学 一种蛋白自组装包埋难溶活性物质纳米制品及其制备方法
CN112107556A (zh) * 2019-06-03 2020-12-22 北京大学 一种含砷纳米药物及其制备方法
CN110051653A (zh) * 2019-06-03 2019-07-26 辽宁大学 一种制备荜茇酰胺白蛋白纳米粒及冻干粉的方法
CN111249254B (zh) * 2020-01-16 2022-02-18 暨南大学 一种包载黄芩苷的叶酸偶联白蛋白纳米粒的制备方法和应用
US20230135752A1 (en) * 2020-03-27 2023-05-04 PhotoQ3 Inc. Medicament for killing tumor cells
CN112972421B (zh) * 2021-02-26 2022-04-08 清华大学 基于多正电荷蛋白的纳米药物系统、其制备方法及应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000074658A1 (en) * 1999-06-02 2000-12-14 Medinova Medical Consulting Gmbh Use of drug-loaded nanoparticles for the treatment of cancers
WO2002089776A1 (de) * 2001-05-05 2002-11-14 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus protein mit gekoppeltem apolipoprotein e zur überwindung der blut-hirn-schranke und verfahren zu ihrer herstellung

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE147976T1 (de) * 1991-01-15 1997-02-15 Hemosphere Inc Protein nanomatrizen und verfahren zur herstellung
US5916596A (en) * 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5543158A (en) * 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
JP2003286199A (ja) * 2002-03-29 2003-10-07 Japan Science & Technology Corp タンパク質中空ナノ粒子を用いる肝臓疾患治療用薬剤
DE102004011776A1 (de) * 2004-03-09 2005-11-03 Lts Lohmann Therapie-Systeme Ag Trägersystem in Form von Nanopartikeln auf Proteinbasis zur zellspezifischen Anreicherung von pharmazeutisch aktiven Wirkstoffen

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000074658A1 (en) * 1999-06-02 2000-12-14 Medinova Medical Consulting Gmbh Use of drug-loaded nanoparticles for the treatment of cancers
WO2002089776A1 (de) * 2001-05-05 2002-11-14 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus protein mit gekoppeltem apolipoprotein e zur überwindung der blut-hirn-schranke und verfahren zu ihrer herstellung

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BALTHASAR S ET AL: "Preparation and characterisation of antibody modified gelatin nanoparticles as drug carrier system for uptake in lymphocytes", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 26, no. 15, May 2005 (2005-05-01), pages 2723 - 2732, XP004673438, ISSN: 0142-9612 *
DINAUER N ET AL: "Selective targeting of antibody-conjugated nanoparticles to leukemic cells and primary T-lymphocytes", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 26, no. 29, October 2005 (2005-10-01), pages 5898 - 5906, XP004931625, ISSN: 0142-9612 *
LANGER K ET AL: "Preparation of avidin-labeled protein nanoparticles as carriers for biotinylated peptide nucleic acid", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM, NL, vol. 49, no. 3, 2 May 2000 (2000-05-02), pages 303 - 307, XP004257171, ISSN: 0939-6411 *
MICHAELIS M ET AL: "Pharmacological activity of DTPA linked to protein-based drug carrier systems", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 323, no. 4, 29 October 2004 (2004-10-29), pages 1236 - 1240, XP004576596, ISSN: 0006-291X *
WARTLICK H ET AL: "Tumour cell delivery of antisense oligonuclceotides by human serum albumin nanoparticles", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 96, no. 3, 18 May 2004 (2004-05-18), pages 483 - 495, XP004505681, ISSN: 0168-3659 *

Also Published As

Publication number Publication date
BRPI0620800A2 (pt) 2016-11-01
US20090181090A1 (en) 2009-07-16
NZ569898A (en) 2011-06-30
ZA200804572B (en) 2009-03-25
RU2404916C2 (ru) 2010-11-27
JP2009521515A (ja) 2009-06-04
DE102005062440A1 (de) 2007-07-05
EP1965769A2 (de) 2008-09-10
DE102005062440B4 (de) 2011-02-24
CA2631003A1 (en) 2007-07-05
CN101346131A (zh) 2009-01-14
KR20080081080A (ko) 2008-09-05
RU2008130167A (ru) 2010-01-27
WO2007073932A2 (de) 2007-07-05
IL192343A0 (en) 2009-02-11
AU2006331030A1 (en) 2007-07-05

Similar Documents

Publication Publication Date Title
WO2007073932A3 (de) Proteinbasiertes trägersystem zur resistenzüberwindung von tumorzellen
WO2007146426A3 (en) Nanoshells for drug delivery
WO2006073950A3 (en) Nanoparticles for protein drug delivery
WO2008151049A3 (en) Nucleic acid functionalized nanoparticles for therapeutic applications
EP3150204A3 (de) Diabetesbehandlung bei patienten mit unzureichender glykämischer kontrolle trotz therapie mit oralem oder nicht-oralem antidiabetikum
WO2006090750A8 (ja) 抗IgSF4抗体及びその利用
WO2007064945A3 (en) Cancer therapies and pharmaceutical compositions used therein
WO2005112886A3 (en) Methods and articles for the delivery of therapeutic agents
TWI319718B (en) Hydrogen-producing fuel processing assemblies, heating assemblies, and methods of operating the same
WO2007146411A3 (en) Nanoshell therapy
EP1940456A4 (de) Wwox-gen, vektoren damit und seine verwendung bei der krebsbehandlung
WO2007118245A8 (en) Methods and compositions related to adenoassociated virus-phage particles
WO2008002479A3 (en) Polymer composite stent with polymer particles
WO2008036929A3 (en) Complex for transferring an anionic substance into a cell
WO2006018632A3 (en) Cell therapy with exo 1
WO2008120998A3 (en) Acoustically sensitive drug delivery particles
WO2009009441A3 (en) Self-assembling complex for targeting chemical agents to cells
WO2008052740A3 (en) Method for stimulating dendritic cells and cell product thus obtained for the autologous immunotherapy of solid human tumours
WO2006137856A3 (en) Method for the production of nanoparticles and microparticles by ternary agent concentration and temperature alteration induced immiscibility
WO2009140675A3 (en) Combination therapy with pm00104 and another antitumor agent
WO2009001099A3 (en) A pharmaceutical composition comprising polyaphron dispersion
WO2006122971A3 (en) Treatment of disease using an improved regulated expression system
WO2008110374A3 (de) Pellets enthaltend pharmazeutische substanz, verfahren zu deren herstellung und deren verwendung
WO2007093451A3 (en) Multimodal imaging using a three compartment polymer nanoparticle with cell specificity
MX2011006773A (es) Biomarcador.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680049072.9

Country of ref document: CN

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2631003

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006841159

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/008125

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 12008501539

Country of ref document: PH

Ref document number: 3238/CHENP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2008547893

Country of ref document: JP

Ref document number: 12087175

Country of ref document: US

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06841159

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 569898

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2008130167

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 2006331030

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020087018409

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2006331030

Country of ref document: AU

Date of ref document: 20061222

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006331030

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2006841159

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0620800

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080624